Central Department of Zoology, Institute of Science and Technology, Tribhuvan University, Kathmandu, 44601, Nepal.
Central Department of Microbiology, Institute of Science and Technology, Tribhuvan University, Kathmandu, 44601, Nepal.
J Clin Virol. 2024 Oct;174:105721. doi: 10.1016/j.jcv.2024.105721. Epub 2024 Aug 30.
Dengue virus (DENV) is one of the most significant mosquito-borne diseases in Nepal. In 2023, DENV outbreaks began in Eastern Nepal, near the border with India, and rapidly spread nationwide. The study aims to describe the outbreak's epidemiological pattern, laboratory characteristics, DENV serotypes, and genotypes. A hospital-based cross-sectional study was conducted in four hospitals in Jhapa, Eastern Nepal, in 2023. Acute serum samples were obtained from dengue suspected patients within 7 days of illness and subjected to virus isolation, conventional and real-time polymerase chain reaction (RT-PCR), and phylogenetic analysis. Out of 60 samples, 42 (70 %), 11 (18.3 %) and 7 (11.7 %) were primary, secondary and non-dengue infection, respectively. Among 53 dengue confirmed patients, 46 (86.7 %) were positive for NS1 and 12 (22.6 %) were positive for both NS1 and IgM. Out of 42 dengue isolates, a new clade of the cosmopolitan genotype of DENV-2 was the most prevalent (28, 66.7 %), followed by genotype III of DENV-3 (11, 26.2 %) and genotype V of DENV-1 (3, 7.1 %). Genotype III of DENV-3 was first introduced in 2022-2023 in Nepal. Phylogenetic analysis of the E gene revealed the DENV-2 isolates from Nepal had 98 % homologous nucleotide similarity with the strains from India and Bangladesh. To our knowledge, this is the first report of circulating serotypes and genotypes of DENV in Jhapa. Integrating molecular findings into the dengue control plan can enhance surveillance efforts, monitor disease trends, and implement proactive measures to reduce the burden of dengue and prevent fatalities in future outbreaks.
登革热病毒(DENV)是尼泊尔最重要的蚊媒疾病之一。2023 年,DENV 疫情首先在尼泊尔东部与印度接壤的地区爆发,并迅速蔓延至全国。本研究旨在描述疫情的流行模式、实验室特征、DENV 血清型和基因型。2023 年,在尼泊尔东部的贾帕地区的四家医院进行了一项基于医院的横断面研究。从发病后 7 天内的登革热疑似患者中采集急性血清样本,并进行病毒分离、常规和实时聚合酶链反应(RT-PCR)以及系统进化分析。在 60 个样本中,分别有 42 个(70%)、11 个(18.3%)和 7 个(11.7%)为原发性、继发性和非登革热感染。在 53 例确诊的登革热患者中,46 例(86.7%)NS1 呈阳性,12 例(22.6%)NS1 和 IgM 均呈阳性。在 42 株登革热分离株中,最常见的是 DENV-2 的世界性基因型新分支(28 株,66.7%),其次是 DENV-3 的基因型 III(11 株,26.2%)和 DENV-1 的基因型 V(3 株,7.1%)。DENV-3 的基因型 III 于 2022-2023 年首次在尼泊尔出现。E 基因的系统进化分析显示,来自尼泊尔的 DENV-2 分离株与来自印度和孟加拉国的菌株具有 98%同源性核苷酸相似性。据我们所知,这是尼泊尔首例报告的 DENV 循环血清型和基因型。将分子发现纳入登革热控制计划可以加强监测工作,监测疾病趋势,并采取积极措施减轻未来疫情的负担并防止死亡。